IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Investor Presentation
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals reported Q4 FY25 revenue of ₹527.8 Cr, up 4.7% year-on-year, with EBITDA rising 17.1% to ₹67.5 Cr at a 12.7% margin. However, full-year FY25 revenue slipped to ₹2,079.2 Cr from ₹2,132.8 Cr, with EBITDA falling to ₹224.6 Cr (margin 10.7% vs 12.1%) and profit after tax declining to ₹101 Cr from ₹135.4 Cr (EPS ₹3.44 vs ₹4.61). During the year the company commissioned a new 10,800 MTPA Paracetamol Unit-11 (₹155.5 Cr investment), expanded Clopidogrel capacity, and secured EDQM CEP certifications for Mesalazine and Quetiapine Fumarate along with Chinese approval for Ibuprofen. Management outlined a forward plan to lift export revenue share to ~40%, grow the non-Ibuprofen API mix, and pursue margin expansion over the next 2–3 years, supported by 101 acres of newly acquired land. The balance sheet remains nearly debt-free with a net debt-to-equity ratio of 0.09.
Q4 shows a recovery in margins, but the full-year picture is weak with declining profitability and operating cash flow. New capacity additions and regulatory approvals support the long-term growth story, though investors will watch for actual margin recovery and execution on export targets before the stock re-rates.